Esperion Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.04 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $3.18Price as of 10 Jul 2026 Data confidenceNot applicable Market Cap $819.5M Enterprise Value $913.4M Shares Outstanding 257.7M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Esperion Therapeutics entered into a definitive agreement on May 1, 2026, to be acquired by healthcare-focused investment firm ARCHIMED for $3.16 per share in cash at closing, plus a non-tradeable Contingent Value Right (CVR) worth up to $100 million in aggregate milestones. The transaction represents a total equity value of up to approximately $1.1 billion. Because the stock is trading extremely close to the $3.16 cash merger price (around $3.15) and the HSR waiting period expired on June 15, 2026, the stock behaves as a merger arbitrage play. The primary upside remains tied to the non-tradeable CVR milestones based on future sales of Nexletol/Nexlizet and Enbumyst. Consequently, a 'Hold' recommendation is appropriate as the stock's independent public trading lifecycle is expected to conclude in Q3 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$3.16 Mean target$3.20 High · most bullish analyst$3.28 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The merger fails to obtain stockholder approval at the July 8, 2026 meeting or is blocked by unforeseen regulatory hurdles, causing the stock to fall back to its pre-announcement trading levels near $2.00. Base CaseCentral scenario The merger with ARCHIMED successfully closes in Q3 2026 following the Special Meeting of Stockholders on July 8, 2026. Shareholders receive $3.16 per share in cash upfront, and the company is delisted from the NASDAQ. Bull CaseUpside scenario Esperion's bull case is driven by the commercial acceleration of its core cholesterol-lowering therapies, Nexletol and Nexlizet, following expanded FDA labels for cardiovascular risk reduction. This expansion significantly broadens its addressable market, particularly among statin-intolerant patients, by targeting both LDL cholesterol and inflammation. The bull case is further supported by robust retail prescription growth, a clear path toward sustainable profitability, and strategic portfolio diversification—such as the acquisition of Corstasis Therapeutics and its FDA-approved heart failure treatment, Enbumyst—which leverages Esperion's existing cardiometabolic sales infrastructure. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |